Search PubMed⌕ Search

Biomedical subjects

F Lee

Publications and source records attributed to F Lee.

330 records · Page 19Linked to original sources

The impact of managed behavorial healthcare on the costs of psychiatric and chemical dependency treatment.

As Congress debates the Health Security Act, a key issue centers on whether and how to include mental health and substance abuse benefits and how to contain costs if and when these benefits are paid at parity with general healthcare. Previous studies estimating the average annual cost of providing behavioral healthcare services have shown considerable divergence, depending on the nature of the defined population and the inclusion of various benefit categories, out-of-pocket expense and administrative costs. Experience from 14 members of the American Managed Behavioral Healthcare Association (AMBHA) is used to define the key features of managed behavioral healthcare, and to demonstrate that a properly managed behavioral healthcare benefit can be significantly less costly than the current reform debate would admit. AMBHA companies (which have many years of experience and presently manage the cost and quality of care for over 65 million people in the United States) [See Table 3, page 28], have shown that a specialty managed care approach can achieve not only significant savings to healthcare providers, payers and society, but also improve quality and access to care. Traditional attempts at reducing mental illness benefit coverage costs have entailed limitations on the availability or access to care. These approaches, however, ignored the larger implications to society of untreated mental illness and chemical dependency. When traditional coverages have offered more extensive benefits, they have primarily favored inpatient treatment, thus increasing costs by overemphasizing care of patients at expensive inpatient settings. AMBHA's proposed principles of healthcare reform and recommended benefit packages for behavioral healthcare can be found on page 80 of this magazine.

Cost Control↗

Effects of combretastatin A4 phosphate on endothelial cell morphology in vitro and relationship to tumour vascular targeting activity in vivo.

BACKGROUND: Combretastatin A4 Phosphate (CA4P) is a tubulin binding agent which causes rapid tumour vascular shutdown. It has anti-proliferative and apoptotic effects on dividing endothelial cells after prolonged exposure, but these effects occur on a much longer time scale than the reduction in tumour blood flow. This study compared the time course of CA4P effects on endothelial cell shape and reduction in red cell velocity. METHODS: Endothelial cell area and form factor (1-4 pi x area x perimeter-2) were measured for proliferating and confluent HUVECs after CA4P treatment. Recovery of shape after CA4P and colchicine was compared. Window chamber studies of tumours were used to measure red cell velocity. Results 70% reduction in red cell velocity and 44% reduction in HUVEC form factor occurred by 10 minutes. Proliferating HUVECs underwent greater cell shape change after CA4P, which occurred at lower doses than for confluent cells. Cell shape recovered 24 hours after 30 minutes exposure to CA4P, but not after colchicine. CONCLUSIONS: The similar time course of cell shape change and red cell velocity reduction suggests endothelial cell shape change may be involved early in the in vivo events leading to vascular shutdown. Differences in the recovery from the shape changes induced by CA4P and colchicine could underlie the different toxicity profiles of these drugs.

Animals↗

Sudden death six weeks after a myocardial infarct.

A 56-year-old man died suddenly at Yale-New Haven Hospital six weeks after experiencing a myocardial infarct and subsequent left ventricle aneurysm formation. Clinical course, treatment, radiologic data, and pathologic findings are examined. Differential diagnosis for this patient's sudden demise include cardiac rupture with cardiac tamponade, extension of the myocardial infarct, and massive pulmonary embolus, among others.

Catheters, Indwelling↗

Infectious terror.

Explore the source record for details and available documents.

Democratic Republic of the Congo↗

Long-term follow-up of stages T2-T3 prostate cancer pretreated with androgen ablation therapy prior to radical prostatectomy.

OBJECTIVE: Our previously reported non-randomized clinical trial proved the ability of preoperative androgen ablation therapy (AAT) to decrease positive surgical margins and to down stage a subset of biopsy proven stage T3 cancer. This study focuses on progression of disease in this group over a 4-5 year period. MATERIALS AND METHODS: This study group consisted of 258 consecutive radical prostatectomies that evolved into three groups: 1) 124 patients with clinical stage T2b-c cancer given AAT; 2) 118 patients with clinical stage T2a not given AAT; 3) 16 patients with proven stage T3 by TRUS guided biopsy and given AAT. RESULTS: Comparison of AAT (n = 140) to no AAT (n = 118) resulted in positive surgical margin rates of 15.3% vs. 49.2%. Specimen confined disease had tumor progression as measured by serum prostate specific antigen of 16.9% (15/89) for AAT (pC.001) vs 10% (5/49) for no AAT (p = 0.288). For known stage T3/C, 43.8% (7/16) downstaged, and 85.7% (6/7) were free of disease at 46.7 mos (mean). The 56.3% with nonconfined (persistent) cancer after AAT had progression usually by one year. CONCLUSION: Neoadjuvant androgen ablation therapy before radical prostatectomy decreased by 3-fold the rate of positive surgical margins (+SM). The vast majority of these patients with +SMs were treated with either external beam radiation or AAT. A near two fold increase of specimen confined disease was found in those given AAT (p < .001). However, the rates of progression (16.9% and 10.2% respectively) were greater in the AAT though not statistically significant (p = 0.288).

Androgen Antagonists↗

Cryosurgery of prostate cancer. Use of adjuvant hormonal therapy and temperature monitoring--A one year follow-up.

OBJECTIVE: To determine the clinical outcomes at one year of Stages T2-T3 prostate cancer by cryosurgery utilizing pretreatment with total androgen ablation therapy and temperature monitoring to control the freezing process. Study Group To date, 347 patients have had 356 cryosurgical procedures, 280 have reached one year post treatment. Of these 131 had re-evaluation with prostatic biopsy and serum PSA. METHODS: Transrectal ultrasound (TRUS) measurement of tumor size and biopsy of extraprostatic space was used to stage patients into two main groups: confined (66.6%) versus nonconfined (19.3%). Radiation failures (14.1%) formed a separate group. Failure rates for the 131 men include all cancer diagnosed during the one year period following cryosurgery. RESULTS: The one year failure rate for the study group was 19.8% (26/131). For stages T2a, T2h C, T3 and radiation failures, the rates of positive biopsies were 13.9%, 12.9%, 33.3% and 35%, respectively. For those with local control of cancer (negative biopsy), 80% had prostate specific antigen (PSA) levels of < 0.5 ng/ml. The statistical variables for persistent cancer with prostate specific antigen > 0.5 ng/ml were: sensitivity of 66.7%, PPV of 16.7%, NPV of 98% and specificity of 83.7%. A statistically significant difference exist between stages T2 vs T3 and radiation failures (p = < 0.5). Major complications of rectal fistula and total incontinence for previously non-treated cancer versus radiation failures were 0.33% and 8.7% respectively, a 26 times greater risk. CONCLUSION: Results of cryosurgery for all stages of prostate cancer at one year are encouraging, being 80% free of disease (biopsy and prostate specific antigen). The morbidity of the previously non-treated cancers from this procedure for us was minimal with high patient acceptance. For radiation failures a local control rate of 65% was achieved. However, early in our experience significant morbidity did occur and our enthusiasm for attempted salvage was initially tempered.

Aged↗